Marijuana Stocks Newsletter – Wednesday August 29, 2018

GT Biopharma’s Chairman and Chief Executive Officer Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Collaboration
Monday was a monumental and reassuring day for those of us involved in the Natural Killer cell (NK) immuno-oncology field. For years, if not decades, visionary researchers such as Dr. Jeffrey Miller at the Masonic Cancer Center, University of Minnesota, understood the potential of NK cells in the treatment of cancers. They remained committed to this concept even as T-cells became the most focused upon immune cell leading to T-cell platforms such as Iovance’s TILs, Amgen’s BiTEs as well as Juno and Kite’s CAR-T. However, each of these platforms and individual therapies has their limitations whether they be safety issues, burden on patients, accessibility issues or cost. Fortunately, a few companies, including GT Biopharma, stayed true to the NK cell hypothesis and continued to drive the science behind this concept.
Click Here For Full Release

Beleave Inc. (BLEVF) Receives First Purchase Order from BC Liquor Distribution Branch
Beleave Inc. (BE.CN) (BLEVF) (“Beleave” or the “Company“) is proud to announce that it has received its first purchase order from the BC Liquor Distribution Branch (“BCLDB“). The Company was selected by the BCLDB as an official supplier earlier last month following a comprehensive approval process.
Click Here For Full Release

Why Did GT Biopharma (GTBP) Have One Of Its Most Active Trading Sessions Of The Year On Tuesday?
It’s clear that companies like Gilead or Merck don’t have any plans on slowing down the M&A trend anytime soon. Gilead’s CEO has even said that the company is “quite interested in things that would augment cellular therapy.”
Yesterday, GT Biopharma (GTBP) made a major announcement that it has initiated a combination trial of its OXS-1550 with a multi-billion dollar oncology drug, owned by a Major Pharmaceutical Company. What is the multi-billion dollar oncology drug?
Click Here To Read Our Full Report

Disclaimer: Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC, Midam Ventures LLC and GT Biopharma, Midam has been paid $200,000 from the company and ZERO shares of GT Biopharma Inc. for a duration beginning July 16, 2018 and ending August 16, 2018. Midam Ventures has been paid an additional $200k by GT Biopharma and has extended its marketing period through Sept 16, 2018. We may buy or sell additional shares of (GTBP) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC, Midam Ventures LLC and Beleave Inc., Midam has been paid $200,000 from the company and ZERO shares of Beleave Inc. for a duration of 6 weeks beginning June 18, 2018 and ending July 31, 2018 NOW EXTENDED TO 8/31/2018. We may buy or sell additional shares of (BLEVF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.